Tag: NIH
-
No Disability Improvement Seen from Clot Device After Stroke
A clinical trial shows devices inserted into an artery after a stroke to remove a blood clot, used with clot-dissolving drugs, do not improve chances of living independently after 90 days compared to the use of drugs alone. The results of the study, funded by National Institute of Neurological Disorders and Stroke, part of the…
-
Clinical Trials To Test More Tamiflu Effects, Plasma on Flu
National Institutes of Health plans three new clinical trials of influenza therapies, two trials involving the current flu drug oseltamivir, and a third trial testing plasma enriched with anti-influenza antibodies. The clinical studies, for which NIH is seeking volunteers, are being held at NIH in Bethesda, Maryland and at 36 other sites elsewhere in the…
-
Personal Genetic Information Vulnerabilty Exposed
Researchers from the Whitehead Institute for Biomedical Research at MIT in Cambridge, Massachusetts were able to identify some 50 people who submitted samples as part of genetic studies with publicly accessible online resources. The team led by Yaniv Erlich of the Whitehead Institute, with colleagues from MIT, Harvard, Baylor College of Medicine in Houston, International…
-
Genetics Company Lands NIH Allergies, Asthma Research Grant
The genetic testing company 23andMe in Mountain View, California received funding from National Institutes of Health for research into the genetics of allergies and asthma. The company also received two other NIH grants, to assess accuracy of new sequencing technologies in clinical applications and develop better genetic research tools based on information in the 23andMe…
-
Rice, Baylor to Study Hydrogel, Stem Cell Scaffolding
Researchers at Rice University in Houston and Baylor College of Dentistry in Dallas received a National Institutes of Health grant to develop an injectable hydrogel that forms an active biological scaffold for tissue repair in a patient. The $1.7 million, five-year project will focus on the regeneration of the dentin-pulp complex found inside human teeth.…
-
Cloud Computing Harnessed for Cancer Data Analysis
Researchers at Johns Hopkins University in Baltimore will collect large volumes of cancer data, down to the level of individual cells, using cloud computing to amass and analyze the data. The team of engineering and medical researchers is led by Denis Wirtz, associate director of Johns Hopkins’s Institute for NanoBio Technology, and funded by a…
-
Pfizer Develops Equine Vaccine from University Research
The Australian division of Pfizer Animal Health in Brisbane released today a new vaccine to prevent disease from the Hendra virus that can be fatal to horses and humans. Pfizer’s Equivac HeV is the product of research conducted at Uniformed Services University of the Health Sciences (USU) and licensed from the Henry M. Jackson Foundation…
-
Antibiotic Found Effective On Drug-Resistant Tuberculosis
Researchers in the U.S. and Korea found the antibiotic linezolid largely effective in treating patients with extensively drug-resistant tuberculosis, who had not responded to previous treatments. The findings of the team led by Clifton Barry of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and Sang-Nae Cho at…
-
Reprogrammed Stem Cells Help Test for Inherited Diseases
Researchers at University of Maryland and Johns Hopkins University in Baltimore, National Institutes of Health, and the company SAIC reprogrammed adult stem cells to develop a test for Gaucher disease and related inherited conditions. The team’s findings appear online in the journal Proceedings of the National Academy of Sciences. The researchers led by Maryland medical…
-
Enrollment Begins for Mesothelioma Vaccine Clinical Trial
Aduro BioTech Inc. in Berkeley, California enrolled the first patient in a clinical trial of a therapeutic cancer vaccine to treat malignant pleural mesothelioma. The trial will test the safety and immune response of Aduro BioTech’s CRS-207 vaccine combined with chemotherapy on patients recently diagnosed with the disease. The phase 1B trial is expect to…